NCT05809024View on ClinicalTrials.gov

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 25, 2025

Study Completion Date

March 25, 2026

Conditions
Locally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer
Interventions
DRUG

letrozole

Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.

Trial Locations (1)

250117

RECRUITING

Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Yongsheng Wang

OTHER